Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab for Prevention of ICANS in CAR T-Cell Therapy
NCT07892027Phase 2Recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Nov 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
A Phase 2 trial of natalizumab in Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), sponsored by University of Michigan Rogel Cancer Center. Started Nov 2026; status: recruiting.
02
Drugs
natalizumab
03
Conditions
Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Beyond the preview
Go deeper on NCT07892027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07892027.